Prosensa Holding N.V., a biotechnology company, engages in the discovery and development of ribonucleic acid-modulating therapeutics for the treatment of genetic disorders. The company's products focus on the treatment of neuromuscular and neurodegenerative disorders, including duchenne muscular dystrophy (DMD), myotonic dystrophy, and huntington's diseases. It develops drisapersen, which is in Phase III studies to restore dystrophin expression and enhancing muscle condition; PRO044 that is in Phase I/II studies to address a separate sub-population of DMD patients; and PRO045, PRO053, PRO052, and PRO055 to address other distinct sub-populations of DMD patients. The company also develops PRO135 that is in preclinical trials for myotonic dystrophy; PRO289, which is in preclinical trials for treating huntington's diseases; and PROSPECT for the rare mutations. Prosensa Holding N.V. was incorporated in 1997 and is based in Leiden, the Netherlands.
China Life Insurance Company Limited, together with its subsidiaries, operates as a life insurance company in China. The company's Individual Life Insurance Business segment sells long-term life insurance and universal life contracts, including term life, whole life, endowment, and annuity products to individuals. Its Group Life Insurance Business segment offers insurance contracts and investment contracts, such as term life, whole life, and annuity products to group entities. The company's Short-Term Insurance Business segment provides short-term insurance contracts, including short-term accident and health insurance contracts. Its Supplementary Major Medical Insurance Business segment sells supplementary major medical insurance contracts to urban and rural residents. China Life Insurance Company Limited offers its products through agents, direct sales representatives, dedicated and non-dedicated agencies, and intermediary bancassurance outlets. The company was founded in 1949 and is headquartered in Beijing, China. China Life Insurance Company Limited is a subsidiary of China Life Insurance (Group) Company.
TASER International, Inc. is engaged in the development, manufacture, and sale of conducted electrical weapons (CEWs) for use in law enforcement, federal, military, corrections, private security, and personal defense markets worldwide. Its CEWs transmit electrical pulses along the wires and into the body affecting the sensory and motor functions of the peripheral nervous system. The company manufactures four hand-held CEW product lines, including TASER X26P, TASER X2, TASER X26, and TASER M26; and TASER eXtended Range Electronic Projectile, a self-contained wireless CEW that deploys from a 12-gauge pump-action shotgun. It also offers consumer products comprising TASER C2 CEW; the TASER StrikeLight, a handheld stun device, integrated with a flashlight; various types of cartridges comprising standard cartridges, Smart cartridges, training cartridges, and others; and other accessories, such as batteries. In addition, the company provides video products, including AXON system that utilizes advanced audio-video record and capture devices worn by first responders to record video of critical incidents from the visual perspective of the officer; the AXON body camera, a body worn camera for law enforcement; EVIDENCE.COM, a cloud-based digital evidence management system and warehouse, offering digital evidence management, sharing, analysis, and storage; and the TASER Cam HD, a video recording device that captures both video and audio of potential and actual TASER use incidents as an accessory to a TASER CEW. TASER International, Inc. sells its products through its direct sales force, distribution partners, online store, and third-party resellers. The company was founded in 1993 and is headquartered in Scottsdale, Arizona.
MGP Ingredients, Inc. produces and sells distillery and ingredients products to the packaged goods industry in the United States, Japan, and Canada. Its Distillery Products segment primarily offers food grade alcohol, fuel grade alcohol, and distillers feed. The company's Ingredient Solutions segment primarily provides specialty wheat starches and proteins, commodity wheat starches, and commodity vital wheat gluten. MGP Ingredients, Inc. sells its products directly or through distributors to the manufacturers and processors of finished packaged goods or to bakeries. The company was founded in 1941 and is headquartered in Atchison, Kansas.
MIND C.T.I. Ltd., together with its subsidiaries, develops, manufactures, and markets real-time and off-line billing and customer care software in the Americas, the Asia Pacific, Africa, Europe, and Israel. The company offers billing and customer care solution supports services, such as voice, data, and content services, as well as prepaid and postpaid payment models in a single platform. It also provides workflow engine to support the creation and execution of business processes, including order management, trouble ticket, and debt collection, as well as integral point of sale solution that covers all dealer, store and cashier management, and sales processes. In addition, the company offers professional services comprising installation, turnkey project implementation services, customer support, training and maintenance services, customization, and project management, as well as managed services, including day to day billing operational tasks primarily to billing and customer care customers. Further, it provides call management systems comprising PhonEX, MEIPS, PhonEX-Ten, and PhonEX-ONE used by organizations for call accounting, telecom expense management, traffic analysis, and fraud detection. The company offers its products directly; and through vendors, systems integrators, and resellers primarily to communication providers, such as traditional wireline and wireless, voice over IP, and broadband IP network operators, as well as through WiMAX, cable, 3G / 4G, and mobile virtual network operators. MIND C.T.I. Ltd. was founded in 1995 and is headquartered in Yokneam Illit, Israel.
Keysight Technologies, Inc. provides electronic measurement solutions to the communications and electronics industries in the United States and internationally. It operates through two segments: Measurement Solutions, and Customer Support and Services. The Measurement Solutions segment sells radio frequency and microwave test instruments and related software, and electronic design automation software tools for use in wireless, and aerospace and defense applications; digital test products that are used by research and development engineers; and voltmeters, multimeters, frequency counters, bench and system power supplies, function generators, and waveform synthesizers, as well as related software that are used by engineers in research and development laboratories. This segment also offers semiconductor and board test solutions, such as parametric test instruments and systems, in-circuit test systems, and laser interferometer measurement systems; surveillance systems and subsystems comprising probes for detecting signals and software, which are used by defense and government engineers and technicians; fiber optic test products, including optical modulation analyzers, component analyzers, power meters, and laser source products; and atomic force and scanning electron microscopes. The Customer Support and Services segment provides repair and calibration services for its customers' installed base of instruments; offers parts and self-maintenance tools; and facilitates the resale of refurbished used equipment. The company sells its products through direct sales force, distributors, resellers, and manufacturer's representatives. Keysight Technologies, Inc. was incorporated in 2013 and is headquartered in Santa Rosa, California. Keysight Technologies, Inc. (NYSE:KEYS.WI) operates independently of Agilent Technologies Inc. as of November 03, 2014.
Northfield Bancorp, Inc. operates as the holding company for Northfield Bank that provides a range of banking services primarily to individuals and corporate customers in Richmond and Kings Counties in New York, and Union and Middlesex Counties in New Jersey. The company's deposit products comprise savings accounts, such as money market, passbook, and statement savings; transaction accounts, including negotiable orders of withdrawal accounts and non-interest bearing demand accounts; certificates of deposit, such as individual retirement accounts; and brokered deposits. Its loan product portfolio includes one-to-four family residential real estate loans, construction and land loans, commercial and industrial loans, and home equity loans and lines of credit. The company also owns a real estate investment trust, which holds primarily mortgage loans and other real estate related investments. It serves customers through its home office located in Staten Island, New York; and 29 additional branch offices situated in Staten Island, Brooklyn, and the New Jersey counties of Union and Middlesex. Northfield Bancorp, Inc. was founded in 1887 and is based in Woodbridge, New Jersey.
Nektar Therapeutics, a clinical-stage biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline comprises drug candidates in therapeutic areas, including oncology, pain, anti-infectives, and immunology. The company's drug candidates in clinical development stage comprise naloxegol, an opioid antagonist, which has completed Phase III clinical trial for treating opioid-induced constipation; BAY41-6551 that is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-181, which has completed Phase II clinical trial for chronic pain; and NKTR-171 that is in Phase I clinical trial to treat neuropathic pain. Its other product candidates comprise etirinotecan pegol, a topoisomerase I inhibitor, which is in Phase III clinical trial for metastatic breast cancer and in Phase II clinical trial for second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat metastatic colorectal cancer that has completed Phase I clinical trial. In addition, the company offers preclinical drug candidates comprising opioid/NKTR-118 to treat chronic pain; NKTR-192 to treat acute pain; and NKTR-214, a cytokine immunostimulatory therapy to treat oncology. Nektar Therapeutics has collaboration with Bayer Healthcare LLC to develop BAY41-6551, which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB to develop and commercialize naloxegol and naloxegol fixed-dose combination program. Further, it has license, manufacturing, and supply agreements with Amgen Inc.; MAP Pharmaceuticals, Inc.; Merck & Co., Inc.; Ophthotech Corporation; Pfizer, Inc.; F. Hoffmann-La Roche Ltd (Roche), Regado Biosciences, Inc.; and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.
Covenant Transportation Group, Inc., together with its subsidiaries, offers truckload transportation and brokerage services in the continental United States. Its Asset-Based Truckload Services segment provides long haul, dedicated, temperature-controlled, and regional solo-driver services. The company also offers freight brokerage services directly, as well as through freight brokerage agents; less-than-truckload consolidation services; and accounts receivable factoring services. It serves transportation companies, such as freight forwarders, less-than-truckload carriers, and third-party logistics providers, as well as traditional truckload customers, including manufacturers, retailers, and food and beverage shippers. As of December 31, 2013, the company operated 2,688 tractors and 6,861 trailers. Covenant Transportation Group, Inc. was founded in 1994 and is headquartered in Chattanooga, Tennessee.
Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company's BD Medical segment produces medical devices that are used in various healthcare settings. This segment's products include needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles used in the treatment of diabetes; prefillable drug delivery systems; anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; and generic prefilled injectables. Its BD Diagnostics segment provides products for the collection and transport of diagnostics specimens; and instrument systems and reagents to detect various infectious diseases, healthcare-associated infections, and cancers. This segment's products comprise integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing systems; molecular testing systems; microorganism identification and drug susceptibility systems; liquid-based cytology systems; rapid diagnostic assays; microbiology laboratory automation; and plated media. The company's BD Biosciences segment offers research and clinical tools that facilitate the study of cells and their components. This segment's products include fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; cell imaging systems; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.